AKT1 and thyroid cancer: For example, inhibitors of signal transduction pathways, as PI3K/AKT inhibitors and MEK/ERK inhibitors, or HDAC inhibitors, have demonstrated the ability to enhance the functional NIS expression in some thyroid cancer, as well as non-thyroid cancer cells[85,117,118] and, very recently, a clinical pilot study has actually demonstrated the effectiveness of the MEK inhibitor selumetinib to increase radioiodide uptake in a number of patients with advanced thyroid cancer[114].